Head and Neck Cancer
A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
- Details
ClinicalTrials.gov ID:
NCT06525220
Diagnosis Type:
NA
USOR Number:
- Address
,
P: